LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
LEXICON PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $680.00K | $1.09M | $1.06M | $1.01M | $1.32M | $1.26M | $1.55M | $1.74M | $1.62M | – | 98.3% | -48.6% |
| License | $0 | $20.00M | $4.30M | $13.15M | $27.54M | $0 | $25.00M | $0 | $0 | – | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Lexicon Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.